HC asks govts. reason for scarcity of Remdesivir drug in Capital

It was hearing plea by a lawyer who is infected

Updated - April 28, 2021 09:28 am IST

Published - April 28, 2021 12:31 am IST - New Delhi

Remdesivir injection

Remdesivir injection

The Delhi High Court on Tuesday asked the Centre and city government on the reason behind the scarcity of Remdesivir drug in the Capital when the medication was being widely prescribed for COVID-19 patients.

Justice Prathiba M. Singh said several companies in India were manufacturing the medicine and millions of vials of the drug must have been exported, “but we do not have enough to cater to our own patients”.

Change in guidelines

“Statistics show that shortage of the drug in Delhi is acute,” the High Court said as it directed the Centre, Drug Controller General of India (DCGI) and Indian Council of Medical Research (ICMR) whether there has been any change in the guidelines with regard to administering Remdesivir.

The court also asked the Central government on what basis it was deciding how much of the drug was to be allocated to Delhi and whether anyone can directly approach the manufactures or suppliers for buying the medicine.

The court was hearing a plea by a lawyer who is suffering from COVID-19 and was able to get only three out of the six doses of Remdesivir required by him.

Acting on the lawyer’s plea, the court directed the Delhi government to ensure the lawyer gets the remaining three vials of the medicine by 9 p.m. tonight.

The court will hear the case again on April 28.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.